{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:50:56Z","timestamp":1770889856782,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"China Antimicrobial Surveillance Network","award":["2018QD100"],"award-info":[{"award-number":["2018QD100"]}]},{"name":"Sumitomo Pharmaceuticals (Suzhou) Co., Ltd"},{"name":"Shanghai Antimicrobial Surveillance Network","award":["3030231003"],"award-info":[{"award-number":["3030231003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10096-025-05175-9","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T06:55:21Z","timestamp":1748415321000},"page":"2067-2075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antimicrobial activity of lefamulin against pathogens most commonly causing community-acquired pneumonia: results from the China antimicrobial surveillance network in 2020\u20132022"],"prefix":"10.1007","volume":"44","author":[{"given":"Li","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siquan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renru","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fupin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"5175_CR1","doi-asserted-by":"publisher","first-page":"106103","DOI":"10.1016\/j.ejps.2021.106103","volume":"170","author":"T Pulingam","year":"2022","unstructured":"Pulingam T, Parumasivam T, Gazzali AM, Sulaiman AM, Chee JY, Lakshmanan M, Chin CF, Sudesh K (2022) Antimicrobial resistance: prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci 170:106103. https:\/\/doi.org\/10.1016\/j.ejps.2021.106103","journal-title":"Eur J Pharm Sci"},{"key":"5175_CR2","unstructured":"(2019) World Health Organization Ten Threats to Global Health in 2019. Available from: https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019. Accessed 14 December 2024"},{"key":"5175_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13756-020-00709-6","volume":"9","author":"H Wushouer","year":"2020","unstructured":"Wushouer H, Zhou Y, Zhang X, Fu M, Fan D, Shi L, Guan X (2020) Secular trend analysis of antibiotic utilisation in China\u2019s hospitals 2011\u20132018, a retrospective analysis of procurement data. Antimicrob Resist Infect Control 9:53. https:\/\/doi.org\/10.1186\/s13756-020-00709-6","journal-title":"Antimicrob Resist Infect Control"},{"key":"5175_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/s1473-3099(20)30596-x","volume":"21","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wei L, Li H, Zhang M, Cao B, Bian J, Zhan S (2021) Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study. Lancet Infect Dis 21:847\u2013857. https:\/\/doi.org\/10.1016\/s1473-3099(20)30596-x","journal-title":"Lancet Infect Dis"},{"key":"5175_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/antibiotics10111370","volume":"10","author":"O Spiller-Boulter","year":"2021","unstructured":"Spiller-Boulter O, Paukner S, Boostrom I, Sands K, Portal EAR, Spiller OB (2021) Determination of in vitro antimicrobial susceptibility for lefamulin (Pleuromutilin) for Ureaplasma spp. And Mycoplasma hominis. Antibiot (Basel) 10:1310. https:\/\/doi.org\/10.3390\/antibiotics10111370","journal-title":"Antibiot (Basel)"},{"key":"5175_CR6","doi-asserted-by":"publisher","first-page":"e02161","DOI":"10.1128\/aac.02161-18","volume":"63","author":"S Paukner","year":"2019","unstructured":"Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS (2019) Antibacterial activity of lefamulin against pathogens most commonly causing Community-Acquired bacterial pneumonia: SENTRY antimicrobial surveillance program (2015\u20132016). Antimicrob Agents Chemother 63:e02161\u2013e02118. https:\/\/doi.org\/10.1128\/aac.02161-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5175_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jgar.2021.10.021","volume":"29","author":"S Paukner","year":"2022","unstructured":"Paukner S, Goldberg L, Alexander E, Das AF, Heinrich S, Patel P, Moran GJ, Sandrock C, File TM Jr., Vidal JE, Waites KB, Gelone SP, Schranz J (2022) Pooled Microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the lefamulin evaluation against pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus Moxifloxacin. J Glob Antimicrob Resist 29:434\u2013443. https:\/\/doi.org\/10.1016\/j.jgar.2021.10.021","journal-title":"J Glob Antimicrob Resist"},{"key":"5175_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/jac\/dkad389","volume":"79","author":"S Paukner","year":"2024","unstructured":"Paukner S, Mendes RE, Arends SJR, Gassner G, Gelone SP, Sader HS (2024) 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms. J Antimicrob Chemother 79:360\u2013369. https:\/\/doi.org\/10.1093\/jac\/dkad389","journal-title":"J Antimicrob Chemother"},{"key":"5175_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3390\/antibiotics10121489","volume":"10","author":"S Paukner","year":"2021","unstructured":"Paukner S, Mariano D, Das AF, Moran GJ, Sandrock C, Waites KB, File TM Jr (2021) Lefamulin in patients with Community-Acquired bacterial pneumonia caused by atypical respiratory pathogens: pooled results from two phase 3 trials. Antibiot (Basel) 10:1489. https:\/\/doi.org\/10.3390\/antibiotics10121489","journal-title":"Antibiot (Basel)"},{"key":"5175_CR10","doi-asserted-by":"publisher","first-page":"39004","DOI":"10.1038\/srep39004","volume":"6","author":"Z Eyal","year":"2016","unstructured":"Eyal Z, Matzov D, Krupkin M, Paukner S, Riedl R, Rozenberg H, Zimmerman E, Bashan A, Yonath A (2016) A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep 6:39004. https:\/\/doi.org\/10.1038\/srep39004","journal-title":"Sci Rep"},{"key":"5175_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40265-020-01443-4","volume":"81","author":"GG Zhanel","year":"2021","unstructured":"Zhanel GG, Deng C, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Berry L, Schweizer F, Zhanel MA, Irfan N, Bay D, Lagac\u00e9-Wiens P, Walkty A, Mandell L, Lynch JP 3rd, Karlowsky JA (2021) Lefamulin: A novel oral and intravenous pleuromutilin for the treatment of Community-Acquired bacterial pneumonia. Drugs 81:233\u2013256. https:\/\/doi.org\/10.1007\/s40265-020-01443-4","journal-title":"Drugs"},{"key":"5175_CR12","doi-asserted-by":"publisher","first-page":"a027110","DOI":"10.1101\/cshperspect.a027110","volume":"7","author":"S Paukner","year":"2017","unstructured":"Paukner S, Riedl R (2017) Pleuromutilins: potent drugs for resistant Bugs-Mode of action and resistance. Cold Spring Harb Perspect Med 7:a027110. https:\/\/doi.org\/10.1101\/cshperspect.a027110","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5175_CR13","doi-asserted-by":"publisher","first-page":"e02158","DOI":"10.1128\/aac.02158-18","volume":"63","author":"RE Mendes","year":"2019","unstructured":"Mendes RE, Paukner S, Doyle TB, Gelone SP, Flamm RK, Sader HS (2019) Low prevalence of Gram-Positive isolates showing elevated lefamulin MIC results during the SENTRY surveillance program for 2015\u20132016 and characterization of resistance mechanisms. Antimicrob Agents Chemother 63:e02158\u2013e02118. https:\/\/doi.org\/10.1128\/aac.02158-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5175_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejps.2014.12.019","volume":"69","author":"JE Agbokponto","year":"2015","unstructured":"Agbokponto JE, Luo Z, Liu R, Liu Z, Liang M, Ding L (2015) Study of Pharmacokinetic interaction of Paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. Eur J Pharm Sci 69:37\u201343. https:\/\/doi.org\/10.1016\/j.ejps.2014.12.019","journal-title":"Eur J Pharm Sci"},{"key":"5175_CR15","doi-asserted-by":"publisher","first-page":"578824","DOI":"10.3389\/fmicb.2020.578824","volume":"11","author":"S Wu","year":"2020","unstructured":"Wu S, Zheng Y, Guo Y, Yin D, Zhu D, Hu F (2020) In vitro activity of lefamulin against the common respiratory pathogens isolated from Mainland China during 2017\u20132019. Front Microbiol 11:578824. https:\/\/doi.org\/10.3389\/fmicb.2020.578824","journal-title":"Front Microbiol"},{"key":"5175_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3138\/jammi-2020-0043","volume":"6","author":"RM Taylor","year":"2021","unstructured":"Taylor RM, Karlowsky JA, Baxter MR, Adam HJ, Walkty A, Lagac\u00e9-Wiens P, Zhanel GG (2021) In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to Lefamulin, a new pleuromutilin. J Assoc Med Microbiol Infect Dis Can 6:149\u2013162. https:\/\/doi.org\/10.3138\/jammi-2020-0043","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"5175_CR17","doi-asserted-by":"publisher","first-page":"e02008","DOI":"10.1128\/aac.02008-16","volume":"61","author":"KB Waites","year":"2017","unstructured":"Waites KB, Crabb DM, Duffy LB, Jensen JS, Liu Y, Paukner S (2017) In vitro activities of lefamulin and other antimicrobial agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the united States, Europe, and China. Antimicrob Agents Chemother 61:e02008\u2013e02016. https:\/\/doi.org\/10.1128\/aac.02008-16","journal-title":"Antimicrob Agents Chemother"},{"key":"5175_CR18","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1128\/aac.00627-16","volume":"60","author":"RE Mendes","year":"2016","unstructured":"Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS (2016) In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including Multidrug-Resistant isolates causing lower respiratory tract infections in the united States. Antimicrob Agents Chemother 60:4407\u20134411. https:\/\/doi.org\/10.1128\/aac.00627-16","journal-title":"Antimicrob Agents Chemother"},{"key":"5175_CR19","unstructured":"Clinical and Laboratory Standards Institute (2024) Performance standards for antimicrobial susceptibility testing; M100 34th. Clin Lab Stand Institute"},{"key":"5175_CR20","unstructured":"Clinical and Laboratory Standards Institute (2023) Performance standards for antimicrobial susceptibility testing; M100 33rd. Clin Lab Stand Institute"},{"key":"5175_CR21","unstructured":"Clinical and Laboratory Standards Institute (2021) Clinical and Laboratory Standards Institute (2020) Performance standards for antimicrobial susceptibility testing; M100 30th. Clin Lab Stand Institute; M43-A. Clin Lab Stand Institute"},{"key":"5175_CR22","unstructured":"(2019) Omadacycline Injection and Oral Products. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/omadacycline-injection-and-oral-products. Accessed 15 December 2024"},{"key":"5175_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12879-023-08166-3","volume":"23","author":"L Zhang","year":"2023","unstructured":"Zhang L, Xiao Y, Zhang G, Li H, Zhao J, Chen M, Chen F, Liu L, Li Y, Peng L, Zhao F, Yang D, Wen Z, Wu L, Wu S, Sun Y, Wang Y, Chen L, Wang X, Wang L, Li W, Qiu H, Chen Y, Gao Z, Ren L, Wang J (2023) Identification of priority pathogens for aetiological diagnosis in adults with community-acquired pneumonia in China: a multicentre prospective study. BMC Infect Dis 23:231\u2013242. https:\/\/doi.org\/10.1186\/s12879-023-08166-3","journal-title":"BMC Infect Dis"},{"key":"5175_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2478\/jtim-2018-0006","volume":"6","author":"YG Zhu","year":"2018","unstructured":"Zhu YG, Tang XD, Lu YT, Zhang J, Qu JM (2018) Contemporary situation of Community-acquired pneumonia in China: A systematic review. J Transl Int Med 6:26\u201331. https:\/\/doi.org\/10.2478\/jtim-2018-0006","journal-title":"J Transl Int Med"},{"key":"5175_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12879-018-3565-z","volume":"18","author":"A Gramegna","year":"2018","unstructured":"Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, Vendrell E, Neves J, Menzella F, Blasi F, Aliberti S, Restrepo MI (2018) Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. BMC Infect Dis 18:677\u2013687. https:\/\/doi.org\/10.1186\/s12879-018-3565-z","journal-title":"BMC Infect Dis"},{"key":"5175_CR26","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1128\/jcm.00321-10","volume":"48","author":"RC She","year":"2010","unstructured":"She RC, Thurber A, Hymas WC, Stevenson J, Langer J, Litwin CM, Petti CA (2010) Limited utility of culture for Mycoplasma pneumoniae and Chlamydophila pneumoniae for diagnosis of respiratory tract infections. J Clin Microbiol 48:3380\u20133382. https:\/\/doi.org\/10.1128\/jcm.00321-10","journal-title":"J Clin Microbiol"},{"key":"5175_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/22221751.2022.2035194","volume":"11","author":"J Qu","year":"2022","unstructured":"Qu J, Zhang J, Chen Y, Huang Y, Xie Y, Zhou M, Li Y, Shi D, Xu J, Wang Q, He B, Shen N, Cao B, She D, Shi Y, Su X, Zhou H, Fan H, Ye F, Zhang Q, Tian X, Lai G (2022) Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China. Emerg Microbes Infect 11:556\u2013566. https:\/\/doi.org\/10.1080\/22221751.2022.2035194","journal-title":"Emerg Microbes Infect"},{"key":"5175_CR28","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG (2019) Diagnosis and treatment of adults with Community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med 200:e45\u2013e67. https:\/\/doi.org\/10.1164\/rccm.201908-1581ST","journal-title":"Am J Respir Crit Care Med"},{"key":"5175_CR29","doi-asserted-by":"publisher","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK (2020) Surveillance of Omadacycline activity tested against clinical isolates from the united States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018. Antimicrob Agents Chemother 64. https:\/\/doi.org\/10.1128\/aac.02488-19","DOI":"10.1128\/aac.02488-19"},{"key":"5175_CR30","doi-asserted-by":"publisher","unstructured":"Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS (2019) Antimicrobial activity of Omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: results from the SENTRY antimicrobial surveillance program (2013 to 2016). https:\/\/doi.org\/10.1128\/aac.02262-18. Antimicrob Agents Chemother 63","DOI":"10.1128\/aac.02262-18"},{"key":"5175_CR31","doi-asserted-by":"publisher","first-page":"1181633","DOI":"10.3389\/fcimb.2023.1181633","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Liu L, Zhang H, Guo J, Wei X, Xue M, Ma X (2023) Severe problem of macrolides resistance to common pathogens in China. Front Cell Infect Microbiol 13:1181633. https:\/\/doi.org\/10.3389\/fcimb.2023.1181633","journal-title":"Front Cell Infect Microbiol"},{"key":"5175_CR32","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1080\/22221751.2022.2078228","volume":"11","author":"X Wang","year":"2022","unstructured":"Wang X, Li M, Luo M, Luo Q, Kang L, Xie H, Wang Y, Yu X, Li A, Dong M, Huang F, Gong C (2022) Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020. Emerg Microbes Infect 11:1508\u20131517. https:\/\/doi.org\/10.1080\/22221751.2022.2078228","journal-title":"Emerg Microbes Infect"},{"key":"5175_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13756-019-0576-5","volume":"8","author":"F Zhao","year":"2019","unstructured":"Zhao F, Li J, Liu J, Guan X, Gong J, Liu L, He L, Meng F, Zhang J (2019) Antimicrobial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China. Antimicrob Resist Infect Control 8:143. https:\/\/doi.org\/10.1186\/s13756-019-0576-5","journal-title":"Antimicrob Resist Infect Control"},{"key":"5175_CR34","doi-asserted-by":"publisher","first-page":"e2220949","DOI":"10.1001\/jamanetworkopen.2022.20949","volume":"5","author":"K Kim","year":"2022","unstructured":"Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E (2022) Global trends in the proportion of Macrolide-Resistant Mycoplasma pneumoniae infections: A systematic review and Meta-analysis. JAMA Netw Open 5:e2220949. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.20949","journal-title":"JAMA Netw Open"},{"key":"5175_CR35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","volume":"7","author":"S Pereyre","year":"2016","unstructured":"Pereyre S, Goret J, B\u00e9b\u00e9ar C (2016) Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 7:974. https:\/\/doi.org\/10.3389\/fmicb.2016.00974","journal-title":"Front Microbiol"},{"key":"5175_CR36","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.21037\/jtd.2017.09.75","volume":"9","author":"YD Yin","year":"2017","unstructured":"Yin YD, Wang R, Zhuo C, Wang H, Wang MG, Xie CM, She DY, Yuan X, Wang RT, Cao B, Liu YN (2017) Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study. J Thorac Dis 9:3774\u20133781. https:\/\/doi.org\/10.21037\/jtd.2017.09.75","journal-title":"J Thorac Dis"},{"key":"5175_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/jcph.2358","volume":"64","author":"P Waitayangkoon","year":"2024","unstructured":"Waitayangkoon P, Moon SJ, Tirupur Ponnusamy JJ, Zeng L, Driban J, McAlindon T (2024) Long-Term safety profiles of macrolides and tetracyclines: A systematic review and Meta-Analysis. J Clin Pharmacol 64:164\u2013177. https:\/\/doi.org\/10.1002\/jcph.2358","journal-title":"J Clin Pharmacol"},{"key":"5175_CR38","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1093\/ofid\/ofy344","volume":"6","author":"MA Pfaller","year":"2019","unstructured":"Pfaller MA, Cormican M, Flamm RK, Mendes RE, Jones RN (2019) Temporal and geographic variation in antimicrobial susceptibility and resistance patterns of Enterococci: results from the SENTRY antimicrobial surveillance program, 1997\u20132016. Open Forum Infect Dis 6:S54\u2013S62. https:\/\/doi.org\/10.1093\/ofid\/ofy344","journal-title":"Open Forum Infect Dis"},{"key":"5175_CR39","doi-asserted-by":"publisher","first-page":"127221","DOI":"10.1016\/j.micres.2022.127221","volume":"266","author":"L Li","year":"2023","unstructured":"Li L, Ma J, Yu Z, Li M, Zhang W, Sun H (2023) Epidemiological characteristics and antibiotic resistance mechanisms of Streptococcus pneumoniae: an updated review. Microbiol Res 266:127221. https:\/\/doi.org\/10.1016\/j.micres.2022.127221","journal-title":"Microbiol Res"},{"key":"5175_CR40","doi-asserted-by":"publisher","first-page":"107366","DOI":"10.1016\/j.ijantimicag.2024.107366","volume":"64","author":"Y Cao","year":"2024","unstructured":"Cao Y, Zhu J, Liang B, Guo Y, Ding L, Hu F (2024) Assessment of lefamulin 20 \u039cg disk versus broth microdilution when tested against common respiratory pathogens. Int J Antimicrob Agents 64:107366. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107366","journal-title":"Int J Antimicrob Agents"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05175-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:07:42Z","timestamp":1758719262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05175-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5175"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05175-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}